AMLX
Amylyx Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$27.33
+3.76%Year over year
Reported trailing growth
- Revenue
- +100.0%
- EBITDA
- +22.4%
- EBIT
- +17.7%
- EPS
- +43.6%
- Free cash flow
- +23.5%
- Operating cash flow
- +23.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +46.6%
- EPS
- -3.6%
Three-year CAGR
- Revenue
- -100.0%
- EBITDA
- +50.5%
- EBIT
- +51.3%
- Net income
- +52.0%
- EPS
- +65.5%
- Free cash flow
- +26.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026